AJNA BioSciences
AJNA BioSciences is a clinical-stage botanical pharmaceutical company developing FDA-regulated cannabinoid and psilocybin-based drugs for Autism Spectrum Disorder, Generalized Anxiety Disorder, and Post-Traumatic Stress Disorder, operating from a DEA Schedule 1-registered facility in Littleton, Colorado.
- Company typePrivate
- Founded2023
- HeadquartersLittleton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AJNA BioSciences does
AJNA BioSciences is a clinical-stage botanical pharmaceutical developer incorporated as a Delaware Public Benefit Corporation and headquartered in Littleton, Colorado. The company is developing a pipeline of FDA-regulated botanical drugs targeting Central Nervous System (CNS) disorders, including Autism Spectrum Disorder (ASD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD). Its lead asset, AJA001 (DeFloria™), is a multi-cannabinoid full-spectrum formula that completed Phase 1 trials and received IND clearance for Phase 2 in ASD in 2025; AJA002 is a tryptamine/psilocybin microdose formula for GAD, AJA003 is a multi-cannabinoid formula for PTSD, and AJA004 is a tryptamine formula for an undisclosed indication.
The company's underlying platform combines patented genetics and a controlled farm-to-lab cultivation process with proprietary Chemistry, Manufacturing, and Controls (CMC) protocols to standardize complex botanical extracts for FDA review. Operations are anchored in a 13,500 ft² Denver-area facility registered for DEA Schedule 1 handling that integrates cultivation, extraction, and analytical instrumentation. AI/ML applications include literature mining for botanical candidate identification and metabolomics-driven mapping of multi-compound interactions to support standardization. The team draws on FDA veterans with 500+ IND/NDA reviews and is led by Chief Medical Advisor Dr. Orrin Devinsky, who led the principal investigation for Epidiolex, the first FDA-approved cannabis drug.
AJNA's business model is premised on prescription pharmaceutical sales following FDA approval, supplemented by optionality for licensing, partnerships, or strategic exits on individual drug candidates. AJA001 is being advanced through the DeFloria LLC joint venture, in which AJNA and Charlotte's Web each hold 40% and British American Tobacco holds 20% following a $10 million investment in April 2023. The company is pre-revenue and has raised over $27 million to date, including a 2024 SEC Rule 506(b) offering and follow-on 2025 tranches, with no currently marketed products.
AJNA BioSciences firmographics
Firmographics- Name
- AJNA BioSciences
- Legal name
- AJNA BioSciences PBC
- Website
- https://ajnabiosciences.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AJNA BioSciences is a clinical-stage botanical pharmaceutical company developing FDA-regulated cannabinoid and psilocybin-based drugs for Autism Spectrum Disorder, Generalized Anxiety Disorder, and Post-Traumatic Stress Disorder, operating from a DEA Schedule 1-registered facility in Littleton, Colorado.
- Ownership category
- akta.pro rank
AJNA BioSciences industry classification
Industry- Product category
- Botanical Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where AJNA BioSciences is headquartered
LocationHeadquarters
- HQ city
- Littleton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AJNA BioSciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Drug Sales: Once FDA-approved, AJNA BioSciences will generate revenue through prescription pharmaceutical sales of botanical drugs targeting Autism Spectrum Disorder, Generalized Anxiety Disorder, and PTSD. The company is pioneering botanical pharmaceuticals in the $678 billion US pharmaceutical market.
- Licensing and Partnership Revenue: Company maintains unique optionality for each drug candidate including exit to or partnership with pharmaceutical leaders, pursuing vertical integration, and/or licensing IP for global reach.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
AJNA BioSciences product offering
Product offeringCore offering
AJNA BioSciences develops a pipeline of FDA-approved botanical pharmaceutical drug candidates that combine nature-derived compounds (full-spectrum cannabinoids and tryptamines including psilocybin) with pharmaceutical-grade Chemistry, Manufacturing, and Controls (CMC) protocols. Its lead candidate AJA001 (DeFloria™) targets irritability in Autism Spectrum Disorder and is in Phase 2 trials; AJA002 (tryptamine microdose) targets Generalized Anxiety Disorder; AJA003 targets PTSD; and AJA004 targets an undisclosed CNS indication. The company manufactures its drug candidates at a 13,500 ft² DEA Schedule 1-registered laboratory integrating cultivation, extraction, and analytical instrumentation, and commercializes them via the DeFloria joint venture with Charlotte's Web and British American Tobacco.
Product overview
AJNA BioSciences is a botanical pharmaceutical company developing a pipeline of FDA-approved botanical drugs targeting Central Nervous System (CNS) disorders. The company operates a platform-based approach combining nature's healing power with pharmaceutical precision, leveraging advanced Chemistry Manufacturing and Controls (CMC) to ensure safety, efficacy, and consistency. The core product portfolio consists of four drug candidates: AJA001 (DeFloria™), a novel cannabinoid formula for Autism Spectrum Disorder currently in Phase 2 trials; AJA002, a tryptamine microdose formula for Generalized Anxiety Disorder entering Phase 1; AJA003, a cannabinoid formula for PTSD in early development; and AJA004, a tryptamine formula for undisclosed indications. The company also operates a DEA Schedule 1-registered laboratory facility in Denver, Colorado for cultivation, extraction, and analytical testing.
Differentiator
Problem solved
Functional benefit
Products and services
- AJA001 (DeFloria™) Novel multi-cannabinoid full-spectrum botanical drug candidate leveraging Charlotte's Web patented genetics and optimized bioavailability, developed for the treatment of irritability in Autism Spectrum Disorder (ASD). First FDA-regulated full-spectrum botanical cannabinoid extract advanced through the DeFloria joint venture, currently in Phase 2 clinical trials. Intended for the 7.7 million individuals in the U.S. with ASD who currently have limited treatment options.
- AJA002 Full-spectrum tryptamine formula microdose product being developed as a novel antidepressant for Generalized Anxiety Disorder (GAD), designed with safer and more targeted mechanisms than traditional SSRIs. Currently entering Phase 1 clinical trials. Targets the antidepressant market where over 238 million daily prescriptions were written in 2020, generating $18.8 billion in revenue, amid growing patient dissatisfaction with conventional SSRIs and the rise of grey-market psilocybin microdosing.
- AJA003 Multi-cannabinoid full-spectrum botanical formula being developed for the treatment of Post-Traumatic Stress Disorder (PTSD), targeting veteran populations and other patients who have been self-medicating with unregulated products. Currently in the Discovery/Optimization stage of development at approximately 50% completion.
- AJA004 Full-spectrum tryptamine formula derived from a unique and lesser-known botanical psychedelic species being developed for psychedelic-assisted therapy for an undisclosed CNS indication. Designed to offer a differentiated therapeutic experience from current investigational psychedelic drugs in trials. Currently in the Discovery/Optimization stage of development at approximately 33% completion.
Quantifiable outcome
- Phase 1 trials demonstrated AJA001 to be safe and well-tolerated with formulation optimized for ASD
- +2 more outcomes
Companies that use AJNA BioSciences
Customer profileSegments4 records
Ideal customer profiles2 records
AJNA BioSciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
AJNA BioSciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Charlotte's WebcoreCharlotte's Web co-founder Joel Stanley now serves as CEO of AJNA BioSciences. The company is co-founder and shareholder in DeFloria JV with AJNA. Charlotte's Web provides patented genetics and cultivation expertise for botanical drug development.
- DeFloria (Joint Venture)coreJoint venture between AJNA BioSciences, Charlotte's Web, and BAT (British American Tobacco) to seek FDA approval for proprietary full-spectrum hemp extract botanical drug. BAT acquired 20% stake for US$10 million, with Charlotte's Web and AJNA each owning 40%. The JV is developing AJA001 for autism spectrum disorder under Dr. Orrin Devinsky's leadership.
- Dr. Orrin DevinskycoreChief Medical Advisor for AJNA BioSciences. Director of Comprehensive Epilepsy Center at NYU Langone. Led principal investigation for Epidiolex, the first FDA-approved cannabis drug. Serving as lead investigator for the DeFloria botanical drug project.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
AJNA BioSciences competitors and assessment
Company assessmentEmerging players
- Silo Pharma: Clinical-stage company developing novel psychedelic and traditional pharmaceutical therapeutics for CNS and autoimmune conditions. Emerging peer in psychedelic pharmaceutical development with comparable early-clinical stage and focus areas.
- Beckley Psytech: Private clinical-stage psychedelic medicine company developing psilocybin and other psychedelic-based therapies. Emerging peer in psychedelic CNS drug development with similar early-clinical stage profile.
- Bright Minds Biosciences: Clinical-stage drug development company focused on novel serotonergic compounds for CNS disorders including epilepsy and depression. Emerging peer with overlapping CNS drug development focus and comparable company size.
Direct peers
- GH Research: Clinical-stage biopharmaceutical company developing novel psychedelic-based therapies (5-MeO-DMT) for treatment-resistant depression. Direct comparable in novel tryptamine CNS drug development.
- Charlotte's Web Holdings: Cannabinoid wellness company and 40% co-owner of DeFloria JV with AJNA. Provides patented hemp genetics to AJNA's platform and represents both a direct partner and adjacent competitor in cannabinoid-based CNS therapeutics.
- atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health, including psilocybin-based candidates. Direct peer in botanical/psychedelic CNS drug development with broader pipeline.
- Compass Pathways: Clinical-stage psychedelic pharmaceutical company developing psilocybin therapy for treatment-resistant depression. Direct comparable in CNS psychedelic drug development with overlapping target indications and FDA pathway experience.
- Cybin Inc. Clinical-stage psychedelic therapeutics company developing psilocybin-based and deuterated tryptamine therapies for depression and other CNS disorders. Direct peer with overlapping psilocybin/tryptamine drug candidates.
- MindMed (Mind Medicine): Neuropharmaceutical company developing psychedelic-inspired medicines including LSD and psilocybin analogs for anxiety, ADHD, and CNS disorders. Direct peer in botanical/psychedelic CNS drug pipeline and clinical-stage development.
Broad incumbents
- Jazz Pharmaceuticals: Global biopharmaceutical company that acquired GW Pharma and commercializes Epidiolex, the first FDA-approved cannabis-derived drug. Broad incumbent with established botanical CNS regulatory and commercialization infrastructure relevant to AJNA's path.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
AJNA BioSciences social profiles
Digital presenceAJNA BioSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
AJNA BioSciences leadership team
Management profileNumber of profiles
Profiles8 records
AJNA BioSciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AJNA BioSciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AJNA BioSciences
What does AJNA BioSciences do?
AJNA BioSciences develops a pipeline of FDA-approved botanical pharmaceutical drug candidates that combine nature-derived compounds (full-spectrum cannabinoids and tryptamines including psilocybin) with pharmaceutical-grade Chemistry, Manufacturing, and Controls (CMC) protocols. Its lead candidate AJA001 (DeFloria™) targets irritability in Autism Spectrum Disorder and is in Phase 2 trials; AJA002 (tryptamine microdose) targets Generalized Anxiety Disorder; AJA003 targets PTSD; and AJA004 targets an undisclosed CNS indication. The company manufactures its drug candidates at a 13,500 ft² DEA Schedule 1-registered laboratory integrating cultivation, extraction, and analytical instrumentation, and commercializes them via the DeFloria joint venture with Charlotte's Web and British American Tobacco.
Is AJNA BioSciences a public or private company?
AJNA BioSciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was AJNA BioSciences founded?
AJNA BioSciences was founded in 2023. It employs 11 to 50 people.
Where is AJNA BioSciences based?
AJNA BioSciences is headquartered in Littleton, United States, in the North America region.
How does AJNA BioSciences make money?
Two revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are licensing and Partnership Revenue.
Who are AJNA BioSciences's main competitors?
Emerging players on record are Silo Pharma, Beckley Psytech and Bright Minds Biosciences. Direct peers are GH Research, Charlotte's Web Holdings, atai Life Sciences, Compass Pathways, Cybin Inc. and MindMed (Mind Medicine). Jazz Pharmaceuticals is listed as a broad incumbent.
Does AJNA BioSciences have an API?
No public API is recorded for AJNA BioSciences.
What industry is AJNA BioSciences in?
AJNA BioSciences's product category is Botanical Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 325412 and its SIC code is 2834.